Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of E6201 Plus Dabrafenib for the Treatment of Central Nervous System Metastases (CNS) From BRAF V600-Mutated Metastatic Melanoma

NCT03332589 is registered in ClinicalTrials.gov with Spirita Oncology, LLC as lead sponsor.

NCT NCT03332589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03332589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of E6201 Plus Dabrafenib for the Treatment of Central Nervous System Metastases (CNS) From BRAF V600-Mutated Metastatic Melanoma
Lead sponsor
Spirita Oncology, LLC
Phase
Phase 1
Overall status
Terminated
Start date
July 2, 2018
Completion date
October 11, 2021
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, malignant melanoma